SCHEMBL6092154

SCHEMBL6092154

COc1ccc(C2NC(=O)c3cccc4c3N2CCC4=O)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
KDM4E B2RXH2 11/20 0.39
ALDH1A1 P00352 10/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
HPGD P15428 4/20 0.38
MAPT P10636 4/20 0.38
POLB P06746 1/20 0.38
AGTR1 P30556 2/20 0.35
LMNA P02545 2/20 0.35
HTT P42858 1/20 0.35
KLK7 P49862 1/20 0.35
HSD17B10 Q99714 2/20 0.34
MCOLN3 Q8TDD5 1/20 0.34
PKM P14618 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6088925 0.90 ALDH1A1 (0.48) GAAKMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL6091130 0.88 KDM4E (0.39) GAAKMT2AMEN1KDM4EALDH1A1
SCHEMBL6090250 0.88 ALDH1A1 (0.42) GAAKMT2AMEN1KDM4EALDH1A1
SCHEMBL6091358 0.88 KDM4E (0.39) GAAKDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL6090132 0.88 ALDH1A1 (0.41) GAAKMT2AMEN1KDM4EALDH1A1
SCHEMBL6090310 0.88 MAPT (0.43) GAAKMT2AMEN1KDM4EALDH1A1
SCHEMBL6089910 0.87 GAA (0.39) GAAKMT2AMEN1KDM4EALDH1A1
SCHEMBL6091282 0.85 KDM4E (0.48) GAAKMT2AMEN1KDM4EALDH1A1
SCHEMBL6092303 0.85 KDM4E (0.39) GAAKMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL6089743 0.84 LMNA (0.44) GAAKMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 GAA 2522/4885KMT2A 274/4885MEN1 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.